Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole SCHEMBL4414195 | 0.93 | C5AR1 (0.43) | CREBBPUSP2SMN1; SMN2C5AR1MAPK1 | |
| SCHEMBL2002050 | 0.82 | CREBBP (0.46) | CREBBP | |
| SCHEMBL4260447 | 0.77 | HTR2A (0.38) | USP2SMN1; SMN2MAPK1ESR2NR1H2 | |
| SCHEMBL4410244 | 0.77 | CREBBP (0.33) | CREBBPC5AR1 | |
| SCHEMBL1999535 | 0.76 | CREBBP (0.36) | CREBBPJAK1JAK2TYK2JAK3 | |
| SCHEMBL19667310 | 0.75 | USP2 (0.44) | USP2SMN1; SMN2MAPK1ESR2NR1H2 | |
| SCHEMBL17813927 | 0.74 | NR1H2 (0.44) | USP2SMN1; SMN2C5AR1MAPK1ESR2 | |
| SCHEMBL17813928 | 0.74 | USP2 (0.43) | USP2SMN1; SMN2MAPK1ESR2NR1H2 | |
| SCHEMBL3276399 | 0.74 | UCHL1 (0.44) | USP2SMN1; SMN2MAPK1ESR2NR1H2 | |
| SCHEMBL22744298 | 0.74 | POLB (0.43) | CREBBPUSP2SMN1; SMN2MAPK1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960374-B2 | e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics | PROXIMAGEN LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | CREBBP 2723/4885USP2 4643/4885SMN1; SMN2 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.